Dr. David Healy Addresses Credibility Crisis-at Columbia University Oct. 20

Additional information as of late Wed Oct 19: Although I was assured that attendance for a presentation by Dr. David Healy (at Columbia University School of Public Health on Oct. 20 at 12:30) would be open to the public, a problem seems to have emerged after an AHRP Infomail about…

Former FDA Commissioner says FDA lost public trust

Former FDA Commissioner says FDA lost public trust Mon, 17 Oct 2005 The FDA’s failure to ensure drugs are properly tested in trials designed to detect serious adverse effects,  and the agency’s failure to require follow-up post-marketing studies to be reasonably secure in the knowledge that no lethal drugs are unleashed on the public has…

FDA Suspends ADHD Drug Safety Study-Approves Risperdal for Autistic Children Without Public Hearing

Two actions by the FDA last week demonstrate where the agency’s priority lies—and that priority is NOT to protect public safety, NOT to protect children’s safety. FDA’s priority—as demonstrated by its actions—is approval of new drugs or approval for expanded even dubious uses of patented drugs.

“Some of the children were prescribed anti-psychotics, rather than discontinued from ADHD therapy.”

"That thing I’m worried about…where the MedGuide would help, where it might even warrant a black box, if this is common, where somebody hallucinates and then gets put on an anti-psychotic drug. That would really be something worth making sure it doesn’t happen,"

National Class Action Filed against Drug-maker for Paxil-induced Suicides in Youths

Below a press release from the lawfirm, Baum Hedlund, announces it has filed a class action lawsuit against GlaxoSmithKline  charging the company with fraud, negligence, strict liability, and breach of warranty in its marketing of Paxil (Seroxat) by concealing the risk of suicide.